Research programme: phosphodiesterase 10 inhibitors - Celon PharmaAlternative Names: PDE10 inhibitors - Celon Pharma; Phosphodiesterase 10A inhibitors - Celon Pharma
Latest Information Update: 29 Dec 2015
At a glance
- Originator Celon Pharma
- Class Antipsychotics
- Mechanism of Action Phosphodiesterase 10A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Huntington's disease; Psychotic disorders